Resverlogix Corp. (RVXCF)
USD 0.03
(-2.79%)
USD 0.03
(-2.79%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2022 | 8.11 Million USD | -18.7% |
| 2021 | 9.98 Million USD | 0.0% |
| 2019 | 11.37 Million USD | -30.14% |
| 2018 | 16.28 Million USD | 96.75% |
| 2017 | 8.27 Million USD | -23.82% |
| 2016 | 10.86 Million USD | -72.9% |
| 2015 | 40.09 Million USD | 89.53% |
| 2014 | 21.15 Million USD | 599.14% |
| 2013 | 3.02 Million USD | -85.24% |
| 2012 | 20.49 Million USD | 65.68% |
| 2011 | 12.37 Million USD | 50.79% |
| 2010 | 8.2 Million USD | -2.72% |
| 2009 | 8.43 Million USD | -55.39% |
| 2008 | 18.9 Million USD | -8.71% |
| 2007 | 20.7 Million USD | 38.09% |
| 2006 | 14.99 Million USD | 86.05% |
| 2005 | 8.06 Million USD | -20.96% |
| 2004 | 10.19 Million USD | 278.45% |
| 2003 | 2.69 Million USD | 149.02% |
| 2002 | 1.08 Million USD | 199.12% |
| 2001 | 361.74 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q2 | 7.88 Million USD | 0.0% |
| 2023 Q3 | 7.82 Million USD | -0.77% |
| 2022 Q2 | 10.03 Million USD | -2.61% |
| 2022 Q3 | 10.28 Million USD | 2.5% |
| 2022 FY | 8.11 Million USD | -18.7% |
| 2022 Q1 | 10.29 Million USD | 3.18% |
| 2022 Q4 | 8.11 Million USD | -21.07% |
| 2021 FY | 9.98 Million USD | 0.0% |
| 2021 Q3 | 11.29 Million USD | -19.95% |
| 2021 Q4 | 9.98 Million USD | -11.59% |
| 2021 Q2 | 14.1 Million USD | 32.8% |
| 2021 Q1 | 10.62 Million USD | 0.0% |
| 2020 Q3 | 10.52 Million USD | 0.02% |
| 2020 Q1 | 11.37 Million USD | -6.19% |
| 2020 Q2 | 10.52 Million USD | -7.52% |
| 2019 FY | 11.37 Million USD | -30.14% |
| 2019 Q4 | 12.12 Million USD | -9.29% |
| 2019 Q3 | 13.37 Million USD | -32.71% |
| 2019 Q1 | 16.28 Million USD | 13.08% |
| 2019 Q2 | 19.87 Million USD | 22.01% |
| 2018 Q3 | 12.61 Million USD | -12.09% |
| 2018 Q4 | 14.4 Million USD | 14.21% |
| 2018 Q1 | 8.27 Million USD | -3.33% |
| 2018 Q2 | 14.34 Million USD | 73.29% |
| 2018 FY | 16.28 Million USD | 96.75% |
| 2017 Q1 | 10.86 Million USD | -19.57% |
| 2017 FY | 8.27 Million USD | -23.82% |
| 2017 Q4 | 8.56 Million USD | -12.35% |
| 2017 Q2 | 9.56 Million USD | -11.99% |
| 2017 Q3 | 9.77 Million USD | 2.15% |
| 2016 Q1 | 40.09 Million USD | -3.34% |
| 2016 Q4 | 13.51 Million USD | -36.46% |
| 2016 Q3 | 21.26 Million USD | -33.66% |
| 2016 Q2 | 32.05 Million USD | -20.06% |
| 2016 FY | 10.86 Million USD | -72.9% |
| 2015 Q3 | 49.93 Million USD | -9.17% |
| 2015 Q2 | 54.98 Million USD | 159.88% |
| 2015 FY | 40.09 Million USD | 89.53% |
| 2015 Q1 | 21.15 Million USD | -0.5% |
| 2015 Q4 | 41.48 Million USD | -16.93% |
| 2014 Q1 | 3.02 Million USD | -3.54% |
| 2014 FY | 21.15 Million USD | 599.14% |
| 2014 Q3 | 26.64 Million USD | 627.27% |
| 2014 Q2 | 3.66 Million USD | 21.08% |
| 2014 Q4 | 21.26 Million USD | -20.2% |
| 2013 FY | 3.02 Million USD | -85.24% |
| 2013 Q1 | 20.49 Million USD | 46.26% |
| 2013 Q2 | 5.56 Million USD | -72.84% |
| 2013 Q3 | 4.03 Million USD | -27.54% |
| 2013 Q4 | 3.13 Million USD | -22.22% |
| 2012 FY | 20.49 Million USD | 65.68% |
| 2012 Q1 | 12.37 Million USD | -30.81% |
| 2012 Q2 | 6.03 Million USD | -51.25% |
| 2012 Q3 | 20.74 Million USD | 244.02% |
| 2012 Q4 | 14.01 Million USD | -32.46% |
| 2011 Q4 | 17.88 Million USD | 106.03% |
| 2011 Q1 | 8.2 Million USD | -25.81% |
| 2011 Q3 | 8.67 Million USD | -37.94% |
| 2011 Q2 | 13.98 Million USD | 70.47% |
| 2011 FY | 12.37 Million USD | 50.79% |
| 2010 Q2 | 18.47 Million USD | 119.12% |
| 2010 Q4 | 11.05 Million USD | -26.18% |
| 2010 Q1 | 8.43 Million USD | -17.18% |
| 2010 FY | 8.2 Million USD | -2.72% |
| 2010 Q3 | 14.98 Million USD | -18.93% |
| 2009 Q3 | 11.46 Million USD | -26.2% |
| 2009 FY | 8.43 Million USD | -55.39% |
| 2009 Q4 | 10.18 Million USD | -11.16% |
| 2009 Q2 | 15.53 Million USD | -17.85% |
| 2009 Q1 | 18.9 Million USD | 372.3% |
| 2008 FY | 18.9 Million USD | -8.71% |
| 2008 Q4 | 4 Million USD | -44.92% |
| 2008 Q3 | 7.26 Million USD | -55.19% |
| 2008 Q2 | 16.21 Million USD | -21.69% |
| 2008 Q1 | 20.7 Million USD | -20.18% |
| 2007 FY | 20.7 Million USD | 38.09% |
| 2007 Q4 | 25.94 Million USD | -11.89% |
| 2007 Q2 | 32.78 Million USD | 118.6% |
| 2007 Q1 | 14.99 Million USD | -28.51% |
| 2007 Q3 | 29.44 Million USD | -10.18% |
| 2006 Q2 | 6.36 Million USD | -20.98% |
| 2006 Q1 | 8.06 Million USD | -4.67% |
| 2006 FY | 14.99 Million USD | 86.05% |
| 2006 Q4 | 20.97 Million USD | 411.53% |
| 2006 Q3 | 4.1 Million USD | -35.62% |
| 2005 Q1 | 10.19 Million USD | -1.22% |
| 2005 Q4 | 8.45 Million USD | -10.51% |
| 2005 FY | 8.06 Million USD | -20.96% |
| 2005 Q2 | 9.51 Million USD | -6.69% |
| 2005 Q3 | 9.44 Million USD | -0.71% |
| 2004 Q1 | 2.69 Million USD | 37.8% |
| 2004 FY | 10.19 Million USD | 278.45% |
| 2004 Q4 | 10.32 Million USD | 259.35% |
| 2004 Q3 | 2.87 Million USD | 16.22% |
| 2004 Q2 | 2.47 Million USD | -8.27% |
| 2003 Q3 | 823.97 Thousand USD | -4.83% |
| 2003 Q2 | 865.8 Thousand USD | -19.99% |
| 2003 Q4 | 1.95 Million USD | 137.32% |
| 2003 FY | 2.69 Million USD | 149.02% |
| 2003 Q1 | 1.08 Million USD | -5.33% |
| 2002 Q3 | 238.62 Thousand USD | -5.77% |
| 2002 Q4 | 1.14 Million USD | 378.97% |
| 2002 Q1 | 273.45 Thousand USD | 0.0% |
| 2002 Q2 | 253.22 Thousand USD | -7.4% |
| 2002 FY | 1.08 Million USD | 199.12% |
| 2001 FY | 361.74 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -351198.701% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -314.414% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 23.11% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -1369.789% |
| Rebus Holdings, Inc. | 5000.00 USD | -162200.0% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 93.768% |
| Qrons Inc. | 420.00 USD | -1932042.857% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -953.015% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 70.96% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -1588.665% |
| Skye Bioscience, Inc. | 11.94 Million USD | 32.038% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 79.11% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -12.4% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -10528.127% |
| SQZ Biotechnologies Company | 107.18 Million USD | 92.429% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -466.677% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -11113.985% |
| Mesoblast Limited | 667.9 Million USD | 98.785% |
| Marizyme, Inc. | 22.01 Million USD | 63.139% |
| Genus plc | 1.02 Billion USD | 99.211% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -497.415% |
| Pharming Group N.V. | 462.85 Million USD | 98.247% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -144.943% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -1526.125% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -1194.258% |
| ContraFect Corporation | 20.67 Million USD | 60.757% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -1978.818% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -2023.362% |
| IMV Inc. | 31.33 Million USD | 74.101% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -95.73% |
| MultiCell Technologies, Inc. | 126.22 USD | -6429150.515% |
| ONE Bio Corp. | 70.08 Million USD | 88.421% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -763.584% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 93.685% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -1779.717% |
| Q BioMed Inc. | 3.51 Million USD | -130.834% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 76.932% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -3005.899% |
| Biomind Labs Inc. | 73.81 Thousand USD | -10893.105% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 98.182% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -460.102% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 72.963% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -195.485% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -1080.388% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -211.732% |
| GB Sciences, Inc. | 103.44 Thousand USD | -7744.976% |
| Alpha Cognition Inc. | 2.45 Million USD | -230.931% |
| HST Global, Inc. | 1526.00 USD | -531682.438% |
| CSL Limited | 38.02 Billion USD | 99.979% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -721.384% |
| Halberd Corporation | 10.13 Thousand USD | -80000.681% |
| Enzolytics Inc. | 361.7 Million USD | 97.756% |
| Agentix Corp. | 261.39 Thousand USD | -3004.533% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -332.136% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.821% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 82.988% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -1168.651% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -35521.79% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 9.321% |
| AVAX Technologies, Inc. | 7.37 Million USD | -10.002% |
| Zenith Capital Corp. | 7410.00 USD | -109414.17% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.76% |
| Ember Therapeutics, Inc. | 184.00 USD | -4410226.087% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -2421.706% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -3004.865% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -774.498% |
| Kadimastem Ltd | 2.3 Million USD | -252.201% |
| Helix BioMedix, Inc. | 3.02 Million USD | -168.257% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 84.602% |
| BioStem Technologies, Inc. | 14.56 Million USD | 44.266% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -14113.402% |
| LadRx Corporation | 2.3 Million USD | -251.621% |
| Cell Source, Inc. | 195.17 Thousand USD | -4057.892% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -2194.856% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -2194.856% |
| NovAccess Global Inc. | 62.24 Thousand USD | -12936.563% |
| Affymax, Inc. | 7.44 Million USD | -9.029% |
| Itoco Inc. | 1.4 Million USD | -479.613% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -8383.436% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -7555.66% |
| Mobile Lads Corp. | 52.00 USD | -15605669.231% |
| CytoDyn Inc. | 11.13 Million USD | 27.128% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -5575.937% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -45285.906% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -2005.217% |
| SYBLEU INC | 330.46 Thousand USD | -2355.608% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -1882.063% |
| International Stem Cell Corporation | 5.39 Million USD | -50.557% |
| Bioxytran, Inc. | 137.63 Thousand USD | -5795.901% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 45.907% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 51.053% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -10172.152% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -838.501% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -7.955% |
| Neutra Corp. | 2851.00 USD | -284536.969% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 74.958% |
| PureTech Health plc | 693.97 Million USD | 98.831% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -0.544% |
| IXICO plc | 15.84 Million USD | 48.782% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 2.016% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 92.146% |
| CSL Limited | 38.02 Billion USD | 99.979% |
| Cellectis S.A. | 333.99 Million USD | 97.57% |